Aurinia Pharmaceuticals (AUPH) Net Income towards Common Stockholders (2019 - 2026)

Aurinia Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at $34.4 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 47.17% year-over-year to $34.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.3 million (up 648.47% YoY) and the FY2025 annual result came in at $287.2 million, up 4893.08% from the prior year.
• Net Income towards Common Stockholders was $34.4 million for Q1 2026 at Aurinia Pharmaceuticals, down from $210.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $210.8 million in Q4 2025 and bottomed at -$37.6 million in Q1 2022.
• A 5-year average of $8.3 million and a median of -$9.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 49.62% — and 2025, when it jumped 14171.77%.
• Aurinia Pharmaceuticals' Net Income towards Common Stockholders stood at -$26.0 million in 2022, then slipped by 3.26% to -$26.9 million in 2023, then soared by 105.5% to $1.5 million in 2024, then soared by 14171.77% to $210.8 million in 2025, then sank by 83.7% to $34.4 million in 2026.
• Business Quant data shows AUPH's Net Income towards Common Stockholders at $34.4 million in Q1 2026, $210.8 million in Q4 2025, and $31.6 million in Q3 2025.